TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kala Pharmaceuticals ( (KALA) ) has provided an update.
On September 16, 2025, the Board of Directors of KALA BIO, Inc. set December 11, 2025, as the date for its annual meeting of stockholders. The company has established deadlines for stockholder proposals, which must comply with the Securities Exchange Act and the company’s by-laws. Proposals must be submitted by October 1, 2025, to be included in the proxy materials. The delay in the meeting date requires stockholders to submit nominations or proposals by September 28, 2025, to be considered.
The most recent analyst rating on (KALA) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Kala Pharmaceuticals stock, see the KALA Stock Forecast page.
Spark’s Take on KALA Stock
According to Spark, TipRanks’ AI Analyst, KALA is a Underperform.
Kala Pharmaceuticals faces significant financial difficulties, marked by declining revenues and heavy reliance on debt, which pose serious risks. The technical analysis reflects a strong downtrend, with the stock being oversold, adding to the negative outlook. Valuation is unattractive due to negative earnings and the lack of a dividend, further weighing down the stock’s appeal.
To see Spark’s full report on KALA stock, click here.
More about Kala Pharmaceuticals
Average Trading Volume: 204,514
Technical Sentiment Signal: Buy
Current Market Cap: $122.7M
For a thorough assessment of KALA stock, go to TipRanks’ Stock Analysis page.